SUBSCRIBE
SUBSCRIBE
News   Policy

US FDA Staff Weigh Urinary Effect of Valeant Pharmaceuticals International, GlaxoSmithKline Drug, Advisory Panel to Review Potiga on Wednesday

August 9, 2010 | 
1 min read
Reuters -- U.S. drug reviewers are concerned about urinary retention seen in some patients treated with an experimental epilepsy medicine from GlaxoSmithKline (GSK.L) and Valeant Pharmaceuticals (VRX.N), according to documents released on Monday.
Regulatory
Food and Drug Administration (FDA) Valeant Pharmaceuticals International GSK
MORE ON THIS TOPIC
Vaccine and syringe injection. Doctor hand with syringe. Vaccination of people for prevention, immunization and treatment from virus infection. Medicine, flu shot, test with needle. Vector
Adcomms
Moderna’s once-rebuffed mRNA flu shot to face scrutiny from FDA adcomm
May 22, 2026
 · 
2 min read
 · 
Tristan Manalac
Richard Pazdur
Regulatory
Pazdur declines to announce candidacy for vacated FDA commissioner role
May 20, 2026
 · 
4 min read
 · 
Heather McKenzie
FDA
FDA’s absent leaders, the millions pharma CEOs make, and pancreatic cancer’s momentum
May 20, 2026
 · 
1 min read
 · 
Jef Akst
The COVID-19 vaccine in glass bottles for prevention, immunization, and treatment of coronavirus infection on a green background. Space for text. Concept of medical and vaccine.
COVID-19
FDA’s own report shows no child deaths definitively caused by COVID vaccination
May 19, 2026
 · 
3 min read
 · 
Tristan Manalac